Increasing the prevalence rate of Crohn’s Disease and similar inflammatory bowel diseases, and changing lifestyle have resulted in boosting the Crohn’s Disease Drug market.
Market Size – USD 9.96 Billion in 2018, Market Growth – CAGR of 3.6%, Market Trends – The rising demand for interleukin inhibitor
The global Crohn’s disease drug market is forecast to reach USD 13.72 Billion by 2027, according to a new report by Reports and Data. Crohn’s disease is a chronic condition, which can be defined as an inflammatory bowel disease (IBD). It is also known as regional enteritis or ileitis. The condition results in bowel, intestine, or other areas of the digestive tract to become ulcerated and inflamed. It usually affects the ileum and the beginning of the colon. There is no one specific test for diagnosing the disease. Doctors often combine various tests to confirm the diagnosis of the condition like tests for infection or anemia and fecal occult blood test. There is no cure for the Chrohn’s disease at present, and no one standardized treatment works for all the care users. The goal of the prescribed medications for the condition is minimizing inflammation that triggers the symptoms and signs of the disease. The medicines are also prescribed, aiming at reducing symptoms of diarrhea, pain, bleeding, and eliminate nutritional deficiencies. Treatment of the illness may also involve nutritional supplements, surgery, drugs, or a combination of these therapies. There are various types of medications prescribed for treating the condition. A large number of care users are usually treated with sulfasalazine (Azulfidine). Another frequently prescribed medication is 5-aminosalicylic acid or 5-ASA medication. These medications are effective in reducing inflammation.
Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/2381
The global Crohn’s Disease Drug market is expected to register significant growth throughout the forecast period. The pharmaceutical & healthcare sector has register significant revenue growth over the recent past. Technological advancements in the healthcare and medical sector, availability of latest tools and techniques, increasing investments in the healthcare sector and improving healthcare infrastructure are key factors boosting market growth. In addition, rising funds by several public and private sectors, high adoption of POC diagnosis and home care settings, is further fueling market growth.
The current pandemic has been very challenging for all industries including the healthcare and pharma sector. Shortage of medicines, vaccines and others healthcare facilities is expected to open lucrative growth opportunities for market players in going ahead.
Request a discount on the report @ https://www.reportsanddata.com/discount-enquiry-form/2381
Further key findings from the report suggest
- The Crohn’s Disease Drug market held a market share of USD 9.96 Billion in the year 2018 that is forecasted to grow at a rate of 3.6% during the forecast period.
- In context to Drug Type, the Anti-Interleukin Biologics segment is projected to witness the fastest growth rate of 25.0% during the forecast period, which is expected to occupy 8.0% of the market by 2027. Advancements in this type of drug, associated with new launches and its effectiveness in reducing inflammation associated with the condition is resulting in its growing demand, also contributes to the growth rate of this segment.
- In context to Route of Administration, the Oral segment is projected to witness a faster growth rate of 4.3% during the forecast period, which is expected to occupy 45.0% of the market by 2027. The growth rate witnessed by the segment is attributed to the presence of strong pipeline products and continuous development in various drugs like JAK inhibitors. The ease of its consumption over injectable has a positive impact on the growth rate of this segment.
- In context to Distribution Channel, the Hospitals Pharmacy segment held the largest market share of 40.0% in 2018, with a CAGR of 3.4% during the forecast period. The market share occupied by the Hospitals Pharmacy segment is resultant of rising incidence rate of the condition, increase in the number of in-patient and out-patients, elevation in the number of hospitalization associated with the disease, which results in high demand for medications of the disease from this distribution channel.
- In regards to the region, Asia Pacific is projected to witness the fastest growth rate of 4.1% during the forecast, which is expected to hold 0% of the market by 2027. The growth rate witnessed by the region is resultant of changing lifestyle that triggers the number of patients affected by this condition along with expansion of the health care sector, which is supporting the market growth in this region.
Leading companies operating in the global Crohn’s Disease Drug market
Johnson & Johnson, AbbVie Inc., Galapagos, Celgene, Gilead, Genentech, RedHill Biopharma, Mesoblast, Takeda, and Shire.
To know more about the report @ https://www.reportsanddata.com/report-detail/crohns-disease-drug-market
The report further sheds light on market segmentation and regional bifurcation.
Crohn’s Disease Drug Market Segmentation:
- Drug Type Outlook (Revenue, USD Billion; 2016-2027)
- Aminosalicylates
- Anti-TNF Biologics
- Anti-Integrin Biologics
- MAdCAM-1Inhibitor
- Immunomodulators
- Anti-Interleukin Biologics
- Biosimilars
- JAK Inhibitors
- Smad7 Inhibitors
- Steroids
- Route of Administration Outlook (Revenue, USD Billion; 2016-2027)
-
- Oral
- Injectable
- Distribution Channel Outlook (Revenue, USD Billion; 2016-2027)
- Hospitals Pharmacy
- Online Pharmacy
- Retail Pharmacy
Key Regional Markets:
- North America
- U.S
- Europe
- UK
- France
- Asia Pacific
- China
- India
- Japan
- MEA
- Latin America
- Brazil
Key findings in the report:
- Information about key trends, technological developments, growing focus on drug discovery and investments in research and development activities
- Detailed insights about manufactures, product portfolios, pricing analysis and financial pricing
- Technological developments and detailed analysis in the volatile competitive landscape.
- New strategies adopted by new and emerging market players
- Estimation about manufactures, sales and import and export dynamics
Request a customization of the report @ https://www.reportsanddata.com/request-customization-form/2381
Thank you for reading the research report on global Crohn’s Disease Drug market. Kindly contact us to know more about the customization feature and our team will offer the best suited report as per your requirement.
Read More Related Reports:-
Browse More Reports:
About Reports and Data
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.
Contact Us:
John W
Head of Business Development
Reports and Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: [email protected]
